GATEWAY to Global Voices

Insights from the SELECT Trial: Impact on Cardiovascular Outcomes in Obesity

Issue 4 I Vol. 1 I Jan. 2026

Faculty

Marc-Andre Cornier, MD
Professor of Medicine
James A. Keating Endowed Chair in Diabetes
Director, Division of Endocrinology, Diabetes & Metabolic Diseases
Medical University of South Carolina

Summary

Dr. Marc-Andre Cornier reviewed the pivotal SELECT trial, which evaluated semaglutide 2.4 mg in overweight or obese…

Obesity and Cardiovascular Risk: The Rationale for GLP Therapy with a Focus on Semaglutide

Issue 3 I Vol. 1 I Nov. 2025

Faculty

Marc Cornier, M.D
Professor of Medicine
James A. Keating Endowed Chair in Diabetes
Director, Division of Endocrinology, Diabetes & Metabolic Diseases
Medical University of South Carolina

Summary

The presentation highlights obesity as a major independent risk factor for cardiovascular disease and explains the mechanisms…

Semaglutide in Type 2 Diabetes - Efficacy in Glycemic Control Compared to Other Agents

Issue 2 I Vol. 1 I Sep. 2025

Faculty

Richard Pratley, M.D.
Samuel Crockett Chair in Diabetes Research Medical Director, AdventHealth Diabetes Institute Senior Scientist and Diabetes Program Head, AdventHealth Translational Research Institute Adjunct Professor, Johns Hopkins School of Medicine, Orlando, Florida

Summary

Dr. Richard Pratley reviewed the evidence for semaglutide in type 2 diabetes management, focusing on the SUSTAIN…

Mechanism of Action of GLP-1 Receptor Agonists in Obesity Treatment

Issue 1 I Vol. 1 I Aug. 2025

Faculty

Prof. Donna H. Ryan, MD
Professor Emerita, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA

Summary

This presentation by Dr. Donna Ryan highlights the evolving understanding and therapeutic potential of GLP-1 receptor agonists. Initially used for…